Stockscreener 앱 받기
1.31
4.80%
0.06
시간 외 거래:
1.31
Medicinova Inc 주식(MNOV)의 최신 뉴스
Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsight - GlobeNewswire Inc.
MediciNova receives U.S. patent allowance for ibudilast combo By Investing.com - Investing.com South Africa
MediciNova receives U.S. patent allowance for ibudilast combo - Investing.com
Patent clears path for MediciNova MN-166 combo in glioblastoma - Stock Titan
Medicinova Inc (MNOV) Holds Steady, Consolidating Around the $1.31 MarkCovered Call ETF - newsline.com
MediciNova Inc stock (US58468P2038): Nasdaq biotech share edges higher while valuation metrics stay - AD HOC NEWS
MNOV Q1 2026 Earnings: Narrower Loss Beats Estimates as Pipeline AdvancesFinancial Health Score - newsline.com
MediciNova, Inc. Financial Disclosures & SEC Filings - TradingView
MNOV Q1 2026 Earnings: Narrower-Than-Expected Loss as Clinical Pipeline AdvancesPreliminary Results - newsline.com
MNOV Q1 2026 Earnings: EPS Surpasses Estimates with Narrower Loss; No Revenue ReportedEarnings Season Preview - The Legal Advocate
MNOV Q1 2026 Earnings: Narrower-than-Expected Loss Reported, Shares DipEarnings Beat Alert - The Legal Advocate
MNOV Q1 2026 Earnings: EPS Beat Against Estimates, Cash Burn Concerns Weigh on SharesAnnual Earnings Summary - The Legal Advocate
MediciNova Inc stock (US58468P2038): valuation snapshot as biotech progresses MN-001 trial milestone - AD HOC NEWS
D Boral Capital maintains MediciNova (MNOV) buy recommendation - MSN
H.C. Wainwright Maintains MediciNova(MNOV.US) With Buy Rating, Maintains Target Price $10 - Moomoo
MNOV Q1 2026 Earnings: Smaller-than-Expected Loss Highlights Clinical-Stage ValueDividend Earnings Report - newsline.com
Medicinova (MNOV) Slides 4% as Stock Tests Key Support Near $1.24Cup and Handle - The Legal Advocate
Medicinova (MNOV) Holds Steady at $1.37 as Key Levels Come into FocusNHNL Divergence - newsline.com
MediciNova Completes MN-001-NATG-202 Clinical Trial Evaluating Tipelukast - geneonline.com
MediciNova, Inc. Announces Completion of Last Patient Visit in Phase 2 Trial of MN-001 for Hypertriglyceridemia and NAFLD Associated with Type 2 Diabetes - Quiver Quantitative
Fatty liver, high triglyceride diabetes trial hits final patient visit - Stock Titan
MediciNova Announces Completion of Last Patient Last Visit - GlobeNewswire
MNOV Q1 2026 Earnings: Narrower-than-Expected Loss as Clinical Pipeline AdvancesEarnings Cycle Outlook - Newser
MNOV Q1 2026 Earnings: Drug Development Progress Drives Narrower-than-Expected LossHigh Attention Stocks - Newser
MediciNova Inc stock (US58468P2038): biotech eyes IPF and neurology pipeline as investors watch next - AD HOC NEWS
MSN Money - MSN
MediciNova, Inc.Common Stock (NQ: MNOV - FinancialContent
MediciNova stock (US58468P2038): Earnings update after April study news - AD HOC NEWS
We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth - Yahoo Finance
MNOV Stock Price, Quote & Chart | MEDICINOVA INC (NASDAQ:MNOV) - ChartMill
MediciNova Inc reports results for the quarter ended March 31Earnings Summary - TradingView
MediciNova: Q1 Earnings Snapshot - KTVB
MediciNova, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
MediciNova (MNOV) Q1 2026 results show lower loss and $27.3M cash - Stock Titan
Medici Nova Biotechnology (MNOV.US) will release its earnings report after the market closes on May 15. - Moomoo
MediciNova Inc stock (US58468P2038): Biopharma innovator targeting unmet needs - AD HOC NEWS
TradingKey - TradingKey
What Medicinova (MNOV) is doing to earn customer loyalty (Tick Down) 2026-05-08Viral Momentum Stocks - newser.com
MediciNova Is Maintained at Buy by D. Boral Capital - Moomoo
D. Boral Capital Reiterates Buy Rating for MediciNova (NASDAQ:MNOV) - MarketBeat
Why are smart money investors paying attention to Medicinova (MNOV)? (Institutional Demand) 2026-05-03Popular Picks - newser.com
MediciNova, Inc. (NASDAQ:MNOV) Sees Large Decrease in Short Interest - MarketBeat
MediciNova Heads to ROTH, Puts Late-Stage Pipeline in Investor Spotlight - BriefGlance
MediciNova (NASDAQ: MNOV) proxy targets 247M authorized shares, board elections - Stock Titan
New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation - Weekly Voice
New Peer‑Reviewed Study Reveals Actionable - GlobeNewswire
D. Boral Capital Maintains MediciNova (MNOV) Buy Recommendation - MSN
Researchers found a brain metastasis weakness — MediciNova plans clinical work - Stock Titan
MediciNova (NASDAQ: MNOV) to vote on 147M share increase, director slate - Stock Titan
Valuation Metrics Overview | Medicinova posts narrower than expected loss, 48.4% EPS beatTech Earnings Analysis - The Legal Advocate
MediciNova (MNOV) asks shareholders to approve 147M share increase ahead of June meeting - Stock Titan
MediciNova, Inc. (NASDAQ:MNOV) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
MediciNova (NASDAQ:MNOV) Share Price Crosses Above Two Hundred Day Moving AverageHere's Why - MarketBeat
What is the bear case for Medicinova (MNOV) Stock | Price at $1.48, Down 1.01%McClellan Summation - The Legal Advocate
1.27%
1.43%
자본화:
|
볼륨(24시간):